Pruritus

• CLINICAL_TRIALS withdrawal · 2024-11-22
  Clinical Trial Update: Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch [NA]

  A clinical trial evaluating imiquimod 3.75% as a surrogate model for pruritus (itch) has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2024-05-07
  Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus [Phase 3]

  Phase 3 trial evaluating difelikefalin for pruritus in advanced chronic kidney disease was terminated.

• CLINICAL_TRIALS withdrawal · 2018-05-15
  Clinical Trial Update: A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis [Phase 2]

  A Phase 2 study evaluating Orvepitant for pruritus associated with atopic dermatitis has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2015-01-27
  Clinical Trial Update: Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

  A Boston University–sponsored Merck study evaluating vorinostat for pruritus signaling pathways has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2013-08-20
  Clinical Trial Update: Gabapentin for the Treatment of Pruritus Caused by Burn Injuries in Children [Phase 1]

  This clinical trial update indicates that a Phase 1 study of gabapentin to treat pruritus from burn injuries in children has been withdrawn.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.